Biochemical and immunological characterization of a novel monoclonal antibody against mouse leukotriene B4 receptor 1

Fumiyuki Sasaki1, Tomoaki Koga1*, Kazuko Saeki1, Toshiaki Okuno1, Saiko Kazuno2, Tsutomu Fujimura3, Yasuyuki Ohkawa4, Takehiko Yokomizo1*

1 Department of Biochemistry, Juntendo University School of Medicine, Tokyo, Japan, 2 Laboratory of Proteomics and Biomolecular Science Research Support Center, Juntendo University Graduate School of Medicine, Tokyo, Japan, 3 Laboratory of Bioanalytical Chemistry, Tohoku Medical and Pharmaceutical University, Miyagi, Japan, 4 Division of Transcriptomics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan

* Current address: Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan

* yokomizo-ty@umin.ac.jp

Abstract

Leukotriene B4 (LTB4) receptor 1 (BLT1) is a G protein-coupled receptor expressed in various leukocyte subsets; however, the precise expression of mouse BLT1 (mBLT1) has not been reported because a mBLT1 monoclonal antibody (mAb) has not been available. In this study, we present the successful establishment of a hybridoma cell line (clone 7A8) that produces a high-affinity mAb for mBLT1 by direct immunization of BLT1-deficient mice with mBLT1-overexpressing cells. The specificity of clone 7A8 was confirmed using mBLT1-overexpressing cells and mouse peripheral blood leukocytes that endogenously express BLT1. Clone 7A8 did not cross-react with human BLT1 or other G protein-coupled receptors, including human chemokine (C-X-C motif) receptor 4. The 7A8 mAb binds to the second extracellular loop of mBLT1 and did not affect LTB4 binding or intracellular calcium mobilization by LTB4. The 7A8 mAb positively stained Gr-1-positive granulocytes, CD11b-positive granulocytes/monocytes, F4/80-positive monocytes, CCR2-high and CCR2-low monocyte subsets in the peripheral blood and a CD4-positive T cell subset, Th1 cells differentiated in vitro from naïve CD4-positive T cells. This mAb was able to detect Gr-1-positive granulocytes and monocytes in the spleens of naïve mice by immunohistochemistry. Finally, intraperitoneal administration of 7A8 mAb depleted granulocytes and monocytes in the peripheral blood. We have therefore succeeded in generating a high-affinity anti-mBLT1 mAb that is useful for analyzing mBLT1 expression in vitro and in vivo.
Introduction

Leukotriene B<sub>4</sub> receptor 1 (BLT1) is one of the class A G protein-coupled receptors (GPCRs) for leukotriene B<sub>4</sub> (LTB<sub>4</sub>) [1, 2], which is a pro-inflammatory lipid mediator [3] derived from arachidonic acid [4, 5]. BLT1 is expressed in various leukocytes such as neutrophils [6], eosinophils [2, 7], dendritic cells (DC) [8, 9], monocytes/macrophages [10, 11], mast cells [12], osteoclasts [13], and activated/differentiated T cells [14, 15, 16]. It initiates a cascade of inflammatory responses including recruitment of leukocytes [17, 18, 19, 20, 21], phagocytosis of microbes [22, 23, 24], and production of pro-inflammatory cytokines/chemokines [25, 26, 27, 28]. Although the role of BLT1 in inflammatory responses is well documented, it has been difficult to analyze the cell-specific expression and function of mouse BLT1 (mBLT1) because there has not been a monoclonal antibody (mAb) available to detect mBLT1.

Monoclonal antibodies (mAbs) have long been used as analytical tools for the identification, localization, and quantification of their specific antigens. They also have been used as therapeutic agents for the treatment of human diseases such as rheumatoid arthritis [29, 30, 31] and Crohn’s disease [32, 33, 34]. Highly specific anti-GPCR mAbs are particularly helpful for defining the anatomical localization as well as the biochemical properties of the receptors. These mAbs are used to evaluate GPCR expression in living cells (by flow cytometry and confocal microscopy), membrane extracts (by western blotting), and fixed tissue sections (by immunohistochemistry) [35, 36, 37, 38, 39]. Specific GPCR mAbs have also been used to purify receptors [40, 41], characterize receptor dimers [42, 43, 44], identify receptor-associating protein partners (by co-immunoprecipitation) [45, 46], and stabilize GPCRs for crystallization [47]. Anti-GPCR mAbs are also valuable tools for studying the signaling and functions of orphan receptors. Approximately 80 GPCRs involved in cancer and inflammatory and metabolic disorders have been proposed as possible targets of antibody-based therapy [48]. Because mAbs do not cross the blood-brain barrier because of their high molecular weight, anti-GPCR mAbs could be used to target GPCRs expressed in the periphery. Thus, mAbs have the potential to treat various diseases without adverse effects in the brain [49].

Although specific Abs against variety of antigens, including some GPCRs, have been developed using phage display technology [50, 51, 52], the most common method of generating Abs, by immunizing animals with target protein, has been generally unsuccessful in the case of GPCRs. In fact, most of the available anti-GPCR Abs are polyclonal Abs purified from the serum of animals immunized with synthetic peptides corresponding to amino acid sequences within the amino (extracellular)-terminal and carboxyl (intracellular)-terminal domains and the extra- and intra-cellular loops of the GPCRs. However, commercially available polyclonal Abs often show non-specific reactivity and cross-reactivity with other plasma membrane proteins, making it difficult to clearly distinguish the specific Ab-GPCR binding from non-specific binding.

In the present study, we report the establishment of a highly specific and highly sensitive mAb for endogenous and overexpressed mBLT1 generated by immunization with mBLT1-overexpressing cells.

Materials and methods

Materials

Alexa Fluor (AF) 488-conjugated anti-mouse Immunoglobulin G Ab (anti-mIgG-AF488) was purchased from Thermo Fisher Scientific (Waltham, MA). R-phycoerythrin (PE)-conjugated anti-mIgG and anti-rat IgG (rIgG) Abs were purchased from Beckman Coulter (Brea, CA). Unless otherwise noted, all Abs were purchased from eBioscience/Thermo Fisher Scientific.
Mice
BLT1-deficient (BLT1-KO: Ltb4r1^−/−) mice were generated as described previously [53, 54] and backcrossed with BALB/c or C57BL/6 mice for more than 12 generations. Wild-type (WT) mice (BALB/c) were purchased from Japan SLC (Shizuoka, Japan) or Kyudo (Saga, Japan). All mice were maintained in a filtered-air laminar-flow enclosure in a specific pathogen-free facility and given standard laboratory food and water. All mice were anesthetized by intraperitoneal (i.p.) injection of ketamine (100 mg/kg) and xylazine (10 mg/kg).

Ethics statement
All animal experiments were approved by the Ethical Committee for Animal Experiments in Kyushu University and Juntendo University. All the studies in this manuscript were carried out in accordance with approved guidelines and regulations.

Plasmids
The pCXN2 vector [55] was used for the expression of various GPCRs. Constructs encoding various untagged or N-terminally FLAG-tagged GPCRs were constructed in-house as previously described [56].

Cell culture
L1.2 cells (a murine pre-B lymphoma cell line; kindly gifted by Dr. Eugene C. Butcher, Stanford University) were cultured in RPMI 1640 (Wako) supplemented with 10% fetal calf serum (FCS) (Thermo Fisher Scientific), 2 mM L-glutamate, 1 mM sodium pyruvate, 50 μM 2-mercaptoethanol, 100 U/ml penicillin, and 100 μg/ml streptomycin (P/S). CHO cells (a Chinese hamster ovary cell line; ATCC) were cultured in Ham’s F12 (Wako) supplemented with 10% FCS and P/S. SP2/0-Ag14 cells (a murine myeloma cell line; ATCC) were cultured in DMEM (Wako) supplemented with 10% FCS and P/S. Anti-mBLT1 mAb-producing hybridoma cells were maintained in Hybridoma-SFM (Thermo Fisher Scientific) supplemented with 10% FCS, 5% BM-Condimed (Sigma-Aldrich, St. Louis, MO), 2 mM L-glutamine, and P/S. Anti-Gr-1 (Ly6G/Ly6C) mAb-producing hybridoma cells (RB6-8C5; obtained from Cell Resource Center for Biomedical Research, Tohoku University) and anti-FLAG mAb-producing hybridoma cells (2H8; in-house) [56] were maintained in RPMI 1640 supplemented with 10% FCS and P/S.

Transfection
L1.2 and CHO cells were transfected with expression vectors for various GPCRs using Lipofectamine LTX and PLUS reagent (Thermo Fisher Scientific) according to the manufacturer’s protocol [56].

Establishment of an anti-mouse BLT1 mAb
To establish an anti-mBLT1 mAb, BLT1-WT (Ltb4r1^+/+) and BLT1-KO mice (BALB/c, male and female, 8–10 weeks old) were immunized with L1.2-mBLT1 cells. I.p. injections of 1–5 × 10^7 intact cells were administered once a week for 8 weeks, followed by four weekly immunizations of the same cells together with an equal volume of monophosphoryl lipid A/trehalose dicorynomycolate (MPL/TDM) adjuvant (Sigma-Aldrich). Plasma was collected 3 days after the 1st–8th immunizations. Anti-mBLT1 Ab titers were measured by flow cytometry using mBLT1-overexpressing CHO (CHO-mBLT1) cells and anti-mIgG-AF488. Three days after the final immunization, splenocytes and popliteal lymph node cells were collected and
fused with SP2/0-Ag14 cells at a ratio of 10:1 using 50% (w/v) polyethylene glycerol (Sigma-Aldrich). Cells were resuspended in HAT medium (Hybridoma-SFM medium containing 10% FCS, 5% BM-condimed, 2 mM L-glutamine, 0.1 mM hypoxanthine, 16 μM thymidine, 0.73 μM aminopterin, and P/S) and seeded into 96-well plates. After confirming colony formation, culture supernatant was screened by flow cytometry using CHO-mBLT1 cells and anti-mIgG-AF488. Screening of approximately 1,200 clones identified a positive clone producing the anti-mBLT1 Ab. The monoclonal hybridoma cells were established by limiting dilution, and designated 7A8.

**Antibody purification and labeling**

Abs were affinity-purified from the culture supernatant using Protein G Sepharose (GE Healthcare) according to the manufacturer’s protocol. Affinity-purified mAbs were separated by SDS-PAGE on 10% acrylamide gels and stained with Coomassie brilliant blue. The concentration of purified Ig was determined by UV absorbance at 280 nm. The isotype of the 7A8 mAb was determined using a mouse mAb isotype kit (Hycult biotechnology). Biotinylated 7A8 mAb (7A8-Biotin) or AF488-labeled mAb (7A8-AF488) were prepared using sulfo-succinimidobiotin (Thermo Fisher Scientific) or AF488 carboxylic acid, tetrafluorophenyl ester, bis (triethylammonium salt) (Thermo Fisher Scientific) according to the manufacturer’s protocol, respectively.

**Flow cytometry**

CHO-mBLT1 cells and mock transfectants were incubated with 10-fold-diluted mouse plasma or 2-fold-diluted hybridoma supernatant in PBS/EDTA [phosphate-buffered saline (PBS) with 2 mM disodium ethylenediaminetetraacetic acid (EDTA) (pH 7.4)] containing 2% FCS for 30 min at 4˚C in 96-well V-bottom plates. After washing with PBS/EDTA, cells were stained with 10 μg/ml anti-mIgG-AF488 for 30 min. To detect overexpressed BLT1 and other GPCRs, transfected CHO cells were incubated with 7A8, anti-human BLT1 (hBLT1) (14F11; Becton Dickinson, Franklin Lakes, NJ), anti-human chemokine (C-X-C motif) receptor 4 (hCXCR4) (12G5; Becton Dickinson), or anti-FLAG (2H8; in-house) and then labeled with 1 μg/ml PE-conjugated anti-mIgG or anti-rIgG Abs. For staining of endogenous BLT1, peripheral blood was collected from BLT1-WT and BLT1-KO mice (BALB/c, male, 8–12 weeks old), or WT mice (BALB/c, male, 8–12 weeks old) using heparinized syringe (Novo heparin; Mochida Pharmaceutical, Tokyo, Japan) and peripheral blood leukocytes (PBL) were isolated by sedimentation of red blood cells using 2% dextran 500 (Sigma-Aldrich). After red blood cell lysis with hemolysis buffer (150 mM NH₄Cl, 10 mM NaHCO₃, and 0.1 mM EDTA-Na₂), PBL were incubated with 5 μg/ml anti-CD16/32 mAb (Biolegend, San Diego, CA) to block Fc receptors and stained with 5 μg/ml 7A8-Biotin with 1.25 μg/ml anti-Gr-1-fluorescein isothiocyanate (FITC) (RB6-8C5), 1.25 μg/ml anti-CD11b-allophycocyanin (APC) (M1/70), 5 μg/ml anti-F4/80-PerCP-Cy5.5 (BM8), 2.5 μg/ml anti-CD4-FITC (RM4-5), 0.5 μg/ml anti-CD8alpha-FITC (53–6.7), 5 μg/ml anti-B220-FITC (RA3-6B2; Becton Dickinson), or 2.5 μg/ml anti-mouse chemokine (C-C motif) receptor 2 (CCR2)-PE (#475301; R&D Systems, Minneapolis, MN) mAbs. Then cells were labeled with 1 μg/ml streptavidin (SA)-PE (Thermo Fisher Scientific) or 1 μg/ml SA-FITC (Thermo Fisher Scientific). Splenocytes and lymph node cells were collected from WT mice (C57BL/6J, male, 7–8 weeks). After hemolysis and washing, cells were stained with 2 μg/ml biotinylated anti-mouse TER-119 (TER-119), CD49b (DX5), CD8alpha (53–6.7), CD11b (M1/70), CD11c (N418), B220 (RA3-6B2), and CD25 (PC61.5) mAbs for 30 min, followed by incubation with SA-MicroBeads (Miltenyi Biotech, Bergisch Gladbach, Germany). The naïve CD4⁺ T cells were purified by negative selection using AutoMACS (Miltenyi Biotech).
Biotech) and were then suspended with RPMI1640 medium containing 1 μg/ml anti-CD28 (37.51) mAb, 10% FCS, 50 μM 2-mercaptoethanol, and P/S. Cells were transferred into 24 well plates coated with anti-CD3 (145-2C11) mAb and in vitro differentiated into CD4⁺ T helper cell subsets, type 0 (Th0), type 1 (Th1), and type 2 (Th2) cells in the presence with 10 μg/ml anti-IFNgamma (R4-6A2) and 10 μg/ml anti-IL-4 (11B11) mAbs (Th0), 100 ng/ml Murine IL-12 p70 (Peprotech, Rocky Hill, NJ) and 10 μg/ml anti-IL-4 mAb (Th1), and 50 ng/ml Murine IL-4 (Peprotech) and 10 μg/ml anti-IFNgamma mAb (Th2) for 7 days. Cells were stained with 5 μg/ml 7A8-AF488 or mIgG-AF488. Dead cells were excluded with 7-amino-actinomycin D (7AAD; Becton Dickinson). Cells were analyzed on a FACSCalibur flow cytometer (Becton Dickinson).

Immunofluorescence staining

CHO-mBLT1 cells and mock transfectants were seeded on glass-bottom dishes (Matsunami Glass, Osaka, Japan) coated with collagen (Cellmatrix Type I-P; Nitta Gelatin, Osaka, Japan). After 48 hr, cells were fixed with 4% paraformaldehyde (PFA) in PBS containing 10 mM glycine (PBS-G) for 5 min, washed with PBS-G, blocked with 3% bovine serum albumin (BSA) in PBS for 10 min, and stained with 10 μg/ml 7A8 mAb in PBS containing 1% BSA for 30 min followed by 10 μg/ml anti-mIgG-AF488. After washing with PBS, slides were mounted with Mowiol mounting medium containing 2.5% 1,4-diazobicyclo-[2.2.2]octane and observed by confocal microscopy using a LSM510 instrument (Carl Zeiss, Oberkochen, Germany). Spleens were removed from BLT1-WT and BLT1-KO mice (C57BL/6, male, 20–24 weeks old), fixed with 4% PFA/PBS and blocked with 5% BSA and 0.5% Triton X-100 in PBS for 1 hr, then stained with 10 μg/ml 7A8 and AF647-conjugated anti-Gr-1 mAb. After washing with 0.1% Tween 20 in PBS, sections were stained with a 1:500 dilution of horseradish peroxidase-conjugated anti-mIgG Ab (Rockland Immunochemicals, Limerick, PA), followed by staining with AF488-labeled tyramide (Thermo Fisher Scientific). Nuclei were stained with 1 ng/ml DAPI (Sigma-Aldrich). Sections were observed using a TCS SP8 confocal microscope (Leica Microsystems, Wetzlar, Germany).

Determination of the epitope recognized by 7A8

Four peptides (mBLT1₁₋₂₁: MAANNTSPAAPSSPGMSLSL, mBLT1₇₆₋₉₄: FLHFLARGTWSF REMGCRL, mBLT1₁₅₉₋₁₉₀: TVKWNRTLICAPNYPKHEKVFHLLLFEATG, and mBLT1₂₄₀₋₂₇₁: LVNLVEAGRTVGDKNSPAGQRLARYVLI) were synthesized using a PSSM-8 peptide synthesizer (Shimadzu, Kyoto, Japan). The 7A8 mAb (1 μg/ml) was pre-incubated with 0.005–100 μM of each of the peptides for 30 min at 37°C. L1.2-mBLT1 cells and mock transfectants were incubated with each Ab-peptide mixture for 30 min at 4°C. After washing with PBS/EDTA, cells were stained with 5 μg/ml anti-mIgG-AF488 and analyzed on a flow cytometer.

Surface plasmon resonance (SPR)

The 7A8 mAb was pre-concentrated with 10 mM acetate (pH 5.0) and immobilized on a CM5 sensor chip (GE Healthcare, Chicago, IL) with HBS-EP buffer [0.01 M HEPES (pH 7.4), 0.15 M NaCl, 3 mM EDTA, and 0.05% Surfactant P20] that had been activated with 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide and N-hydroxysuccinimide and blocked with ethanolamine-HCl (pH 8.5). The four peptides (10 μM) were injected individually at a flow rate of
30 μl/min for 2 min. Resonance units (RU) were measured using a Biacore T-200 SPR spectrometer (GE Healthcare).

**Ligand binding assay**

Microsomal fractions (5 μg) of mBLT1-overexpressing CHO and L1.2 cells or mock transfectants were prepared as described previously [57]. Proteins were incubated with 0.5 nM [3H]labeled LTB₄ ([3H]LTB₄) in the presence or absence of 10 μg/ml 7A8 mAb for 1 hr. A control sample for non-specific binding was prepared with the [3H]LTB₄-mAb mixture and 1 μM unlabeled LTB₄. Samples were transferred onto a GF/C filter and washed with binding buffer [50 mM Tris-HCl (pH 7.5), 10 mM MgCl₂, and 10 mM NaCl]. Dried filters were immersed in MicroScint-O scintillation fluid (PerkinElmer, Waltham, MA), and the radioactivity was measured using a TopCount scintillation counter (PerkinElmer).

**Ligand-induced calcium mobilization assay**

Briefly, L1.2-mBLT1 cells, L1.2-FLAG-mBLT1 cells, or mock transfectants were pre-incubated with 7A8 (1 and 10 μg) or control mIgG₁ (10 μg) and then loaded with Fluo 3-acetxymethyl (Dojindo Laboratories, Kumamoto, Japan) in a Hank’s balanced salt solution (HBSS)-based loading buffer containing 20 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (pH 7.4), 2.5 mM probenecid (Sigma-Aldrich), and 0.04% Pluronic F-127 (Thermo Fisher Scientific). Cells were then stimulated with 0.01–1000 nM LTB₄. Assay plates were analyzed using a FlexStation 3 (Molecular Devices, Sunnyvale, CA).

**Depletion assay**

WT mice (BALB/c, female, 8–10 weeks old) were i.p. injected with 100 μg of 7A8, 1A8 (anti-Ly6G mAb; Bio X Cell, West Lebanon, NH), or anti-Gr-1 mAbs, or PBS (as a control). PBL were collected at 1 day after mAb injection as described above (see “Flow cytometry”), and were then stained with mAbs and analyzed by flow cytometry.

**Statistics**

Data are expressed as the mean ± SEM. ANOVA tests were used for multiple comparisons. P-values <0.05 were considered statistically significant. All statistical analyses were performed using Prism, version 5.0 (GraphPad Software, La Jolla, CA).

**Results and discussion**

Establishment of a hybridoma cell line that produces an anti-mouse BLT1 monoclonal antibody

To establish a hybridoma that produces a high-affinity mAb for mBLT1, BLT1-WT and BLT1-KO mice were immunized with L1.2-mBLT1 cells that stably expressed untagged mBLT1 (Fig 1A). After eight i.p. injections of L1.2-mBLT1 cells, mice received four additional immunizations with the same cells plus MPL/TDM adjuvant. Plasma from BLT1-KO mice, but not BLT1-WT mice, was found to be immunoreactive to BTL1 (Fig 1B). Approximately 1,200 hybridoma clones were generated by fusing SP2/0 myeloma cells with splenocytes and lymph node cells from immunized BLT1-KO mice. Culture supernatant from one clone, 7A8, positively stained CHO-mBLT1 cells by flow cytometry. Immunoglobulin was purified from the 7A8 culture supernatant using Protein G Sepharose, and the purity and recovery of 7A8 mAb was analyzed by SDS-PAGE (Fig 1C). The isotype of the 7A8 mAb was determined to be
The average yield of functional 7A8 mAb was approximately 2.3 mg from 100 ml of culture supernatant.

7A8 mAb specifically recognizes mouse BLT1

To confirm the specificity of the 7A8 mAb, mock-transfected cells and cells transfected with FLAG-tagged mBLT1 (FLAG-mBLT1), hBLT1 (FLAG-hBLT1), or hCXCR4 (FLAG-hCXCR4) were stained with purified 7A8 mAb (Fig 2A). Staining with the 7A8 mAb resulted in a 1.5-log shift in fluorescence for FLAG-mBLT1 cells, but not for FLAG-hBLT1 or FLAG-hCXCR4 cells. The 7A8 mAb did not cross-react with other GPCRs, including mouse leukotriene B4 receptor 2 (BLT2) and chemokine (C-C motif) receptor 7 (CCR7), human sphingosine-1-phosphate receptor 1 (SIP1) and cysteinyl leukotriene receptor 1 (CysLT1), and guinea pig platelet-activating factor receptor (PAFR) (data not shown). By immunofluorescence, 7A8 strongly stained CHO-mBLT1 cells but not mock transfectants (Fig 2B). These data demonstrate that 7A8 is a specific mAb for mBLT1.

The 7A8 mAb recognizes the second extracellular loop of mBLT1

To determine the epitope of mBLT1 recognized by 7A8, four peptides with sequences derived from the extracellular domains of mBLT1 (an N-terminal region and three harboring loops) (Fig 3A) were synthesized and used in a competition assay with 7A8. As shown in Fig 3B, the
The binding reactivity of 7A8 was clearly decreased in the presence of a peptide comprising amino acids 159–190 of mBLT1 (mBLT1<sub>159-190</sub>), which is located in the second extracellular loop.

Next, the binding of 7A8 to mBLT1<sub>159-190</sub> was directly examined by SPR (Fig 3C). The 7A8 mAb bound directly to mBLT1<sub>159-190</sub> with an association ($k_a$) and dissociation rate constant ($k_d$) of $1.05 \times 10^4$ M$^{-1}$ s$^{-1}$ and $6.49 \times 10^{-3}$ s$^{-1}$, respectively. The equilibrium dissociation

---

**Fig 2.** The 7A8 mAb detects mBLT1-overexpressing cells. (A) FLAG-mBLT1, FLAG-hBLT1, and FLAG-hCXCR4-overexpressing CHO cells (black outlines) and mock transfectants (gray filled histograms) were stained with anti-mBLT1 (7A8), anti-hBLT1, anti-hCXCR4, and anti-FLAG (2H8) mAbs. (B) Immunofluorescence staining of CHO-mBLT1 cells (right) and mock transfectants (left) using 7A8. DIC: differential interference contrast. Scale bars: 50 μm.

https://doi.org/10.1371/journal.pone.0185133.g002
Fig 3. Determination of the epitope recognized by 7A8 mAb by flow cytometry and SPR. (A) A secondary structure diagram of the expected topology of mBLT1. The extracellular domains of mBLT1 are indicated in gray. (B) Flow cytometry-based competition assay with 7A8 mAb and synthetic peptides corresponding to the extracellular domains of mBLT1 (mBLT1_1-21, mBLT1_76-94, mBLT1_159-190, and mBLT1_240-271). The four peptides (0.005–100 μM) were pre-incubated with 7A8 mAb (1 μg/ml) and then...
constant \( (K_D) \) was \( 6.16 \times 10^{-7} \) M. However, the 7A8 mAb did not inhibit the binding of LTB\(_4\) to mBLT1 (S1A Fig) or LTB\(_4\)-dependent calcium mobilization through mBLT1 (S1B Fig). These data show that 7A8 binds to the liner sequence of amino acids in the second extracellular loop of mBLT1 without affecting ligand binding.

**Detection of endogenous mouse BLT1 with 7A8**

The ability of the 7A8 mAb to detect endogenous mBLT1 was analyzed next. 7A8-Biotin was prepared and used for flow cytometry. As shown in Fig 4A, 7A8-Biotin positively stained Gr-1\(^+\) granulocytes, CD11b\(^+\) granulocytes/monocytes, and F4/80\(^+\) monocytes in the peripheral blood from naïve BLT1-WT mice. No 7A8 staining of naïve CD4\(^+\) T cells, CD8\(^+\) T cells, and B220\(^+\) B cells were observed, consistent with the previously reported lack of BLT1 expression on these cells [16]. Binding of 7A8 to Gr-1\(^+\) granulocytes was not observed in BLT1-KO mice but was not affected by BLT2 deficiency (data not shown), confirming the specificity of the 7A8 mAb. Both CD115\(^+\) (a canonical monocyte marker) and Ly6C\(^+\) (a classical or pro-inflammatory monocyte marker) monocytes expressed BLT1 (data not shown). Further analysis showed that BLT1 was expressed in both CCR2-high (CCR2\(^{hi}\)) inflammatory and CCR2-low (CCR2\(^{lo}\)) resident monocytes (Fig 4B). Furthermore, BLT1 expression was clearly detected only in a subset of CD4\(^+\) T cells, Th1 cells differentiated \textit{in vitro}, but was not obvious in Th0 and Th2 cells (Fig 4C). Taken together, these data indicate that 7A8 is sensitive and specific enough to detect endogenous mBLT1.

**Validation of 7A8 for immunohistochemistry of mBLT1**

In general, it is difficult to stain mouse tissues using monoclonal or polyclonal Abs derived from mouse due to high background staining caused by endogenous mouse IgG and mouse Fc receptors expressed on immune cells such as B cells, macrophages, and DC. We therefore tried to detect mBLT1-expressing cells in the mouse spleen with 7A8 using a tyramide signal amplification system. The 7A8 mAb was able to detect Gr-1\(^+\) granulocytes in the red pulp (RP) and Gr-1\(^+\) monocytic cells (such as monocytes, macrophages, or DC) in the white pulp (WP) of BLT1-WT mice, but 7A8 staining was not observed in BLT1-KO mice (Fig 5). These data clearly show that 7A8 mAb is a highly sensitive and specific mAb for mBLT1.

**Clone 7A8 can deplete granulocytes and monocytes from the peripheral blood**

To examine whether 7A8 can be used for depletion of mBLT1-expressing cells \textit{in vivo}, 7A8, 1A8, or anti-Gr-1 mAbs was administered to WT mice (100 µg/mice, i.p.). PBL were collected and analyzed by flow cytometry at 1 day after mAb injection. As shown in Fig 6A, Gr-1\(^{hi}\)CD11b\(^{hi}\)(CCR2 F4/80\(^+\)) granulocytes and F4/80\(^+\)CD11b-middle (CD11b\(^{mid}\)) (CCR2\(^{lo}\)Gr-1\(^{mid}\)) monocytes were depleted in peripheral blood in either cases; however, CCR2\(^{hi}\)CD11b\(^{hi}\)(F4/80\(^{lo}\)Gr-1\(^{hi}\)) inflammatory monocytes were eliminated only by injection of the 7A8 mAb. The 7A8 administration significantly depleted granulocytes and monocytes (Fig 6B). Administration of 1A8 and anti-Gr-1 mAb depleted most of the granulocytes with some depleting effects on monocyte

https://doi.org/10.1371/journal.pone.0185133.g003
Fig 4. Staining of mouse peripheral blood leukocytes and T cell subsets with 7A8. Flow cytometric analysis of mouse PBL (A, B) and in vitro differentiated CD4+ T cell subsets (C) with 7A8. (A) PBL were stained with 7A8-Biotin and several lineage markers, and staining was analyzed separately in Gr-1+ granulocytes, CD11b+ granulocytes/monocytes, F4/80+ monocytes, CD4+ T cells, CD8+ T cells, and B220+ B cells from naive BLT1-WT (black outlines) and BLT1-KO (gray filled histograms) mice. (B) Monocytes were stained with 7A8-Biotin and anti-CCR2 mAb from the peripheral blood of naive WT mice. The mlgG1-Biotin and rlgG2b mAb were used as isotype controls. (C) Th0, Th1 and Th2 cells were stained with 7A8-AF488 (black outlines) or mlgG-AF488 (gray filled histograms) as a control.
subsets. Thus, the 7A8 mAb will be useful to analyze the physiological and pathophysiological roles of BLT1+ granulocytes and monocytes in vivo.

In this study, we successfully established an anti-mBLT1 mAb (clone 7A8) with high specificity and sensitivity for exogenous (Fig 2) and endogenous (Figs 4 and 5) mBLT1 by immunizing BLT1-KO mice with BLT1-overexpressing cells (Fig 1). Endogenous BLT1 is abundantly expressed in granulocytes, which have a very short life span in vivo. Therefore, WT mice develop peripheral immunological tolerance for BLT1, necessitating the use of BTL1-KO mice for Ab generation. Although several mAbs can be obtained by immunization with a general
antigen (e.g., recombinant fusion protein or plasmid DNA) using gene-deficient mice [58, 59, 60, 61, 62, 63], little has been reported on anti-GPCR mAb generation by this strategy. Thus, this approach might be useful for generating highly specific and sensitive mAbs against other GPCRs and orphan GPCRs. We confirmed that 7A8 can be used for detection of mBLT1 on tissue by immunohistochemistry (Fig 5). In addition, 7A8 significantly depleted BLT1$^+$ granulocytes and monocytes (Fig 6), but not lymphocytes (data not shown), from the peripheral blood. Furthermore, 7A8 bound the second extracellular loop of mBLT1 (Fig 3), and did not affect the LTB$_4$ binding and intracellular signaling (S1 Fig). These results are consistent with previous studies showing that the transmembrane domains III, V and VI of BLT1 are involved

Fig 6. The 7A8 mAb depletes granulocytes and monocytes in vivo. (A, B) WT mice were injected intraperitoneally with 7A8, 1A8, anti-Gr-1 mAbs, or PBS as a control. (A) PBL were collected at 1 day after mAb injection and stained with 7A8, anti-Gr-1, anti-F4/80, and anti-CCR2 mAbs. The staining was analyzed separately in Gr-1 and CD11b (upper panels), F4/80 and CD11b (middle panels), or CCR2 and CD11b (lower panels). (B) The percentages of Gr-1$^+$/CD11b$^+$ (CCR2/Gr-1$^-$) granulocytes (left panel), F4/80$^+$/CD11b$^+$/CCR2$^+$ (Gr-1$^-$) monocytes (middle panel), and CCR2$^+$/CD11b$^+$/F4/80$^-$ (Gr-1$^-$) monocytes (right panel) within total PBL (n = 4–5) are shown. Cont: control. Data were analyzed by one-way ANOVA, followed by the Bonferroni post-hoc test. ns, not significant. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

https://doi.org/10.1371/journal.pone.0185133.g006
in the LTB₄ binding [64, 65, 66]. Our data suggests that 7A8 mAb will be a very useful tool to clarify the physiological and pathophysiological functions of BLT1 in various disease models by quickly eliminating BLT1-expressing cells without inducing the compensatory gene expression caused by BLT1 deficiency. Future studies will examine the effects of depleting BLT1-expressing cells on the onset and progression of several inflammatory diseases in animal models.

We also observed that BLT1 was expressed in circulating CCR2<sup>hi</sup> inflammatory monocytes and CCR2<sup>lo</sup> resident monocytes in the peripheral blood (Fig 4B). The physiological and pathophysiological roles of BLT1 in those subsets are unknown. In general, inflammatory (or classical) monocytes (CCR2<sup>hi</sup> Ly6C<sup>hi</sup> CX<sub>3</sub>CR1<sup>hi</sup>) are recruited to inflamed tissues, where they produce inflammatory cytokines (e.g., IL-1beta and TNF-alpha) in response to infection or tissue damage. They become differentiated into macrophages or DC during acute inflammation and chronic inflammation. In the steady state or during homeostatic inflammation, they become tissue-resident macrophages, which readily engulf dying or dead cells (including apoptotic or necrotic cells) and cellular debris, contributing to the maintenance of tissue homeostasis. Tissue-resident (or non-classical) monocytes (CCR2<sup>lo</sup> Ly6C<sup>lo</sup> CX<sub>3</sub>CR1<sup>hi</sup>) patrol locally to clear cellular debris. These cells can also produce anti-inflammatory cytokines (e.g., IL-10), although their cellular function is not fully understood [67, 68, 69]. Recent reports show that both monocyte subsets (classical and non-classical) can polarize into alternatively activated (or M2-type) macrophages [70, 71, 72], although the molecular mechanisms of this conversion remain poorly understood. Future studies in our group will investigate the functions of BLT1 in both classical and non-classical monocytes using the 7A8 mAb.

Supporting information
S1 Fig. 7A8 mAb does not affect interaction of LTB₄ and mBLT1. (A) Competitive binding assay of 7A8 mAb with a radioactive ligand. Microsomal fractions were mixed with [³H]LTB₄, and added with or without 7A8 (Total). A non-specific binding (NS) was determined with 2,000-fold concentration of non-labeled LTB₄ in the same preparation (n = 2–3 for Total, n = 2 for NS). Data were analyzed by one-way ANOVA, followed by the Newman-Keuls post-hoc test: ns, not significant. (B) The effect of 7A8 on LTB₄-BLT1 signaling. L1.2-mBLT1, L1.2-FLAG-mBLT1 cells or mock transfectants were incubated with 7A8 mAb, and calcium mobilization was measured by stimulation with LTB₄ (n = 2–3). RFI: relative fluorescent intensity. Data were analyzed by two-way ANOVA: ns, not significant. (TIF)

Acknowledgments
We thank Dr. Junichi Miyazaki (Osaka University) for supplying pCXN2, the Research Center for Human Disease Modeling (Kyushu University), and the Research Support Center of the Division of Molecular and Biochemical Research (Juntendo University) for technical support.

Author Contributions
Conceptualization: Fumiyuki Sasaki, Takehiko Yokomizo.
Data curation: Fumiyuki Sasaki.
Formal analysis: Fumiyuki Sasaki.
Funding acquisition: Tomoaki Koga, Kazuko Saeki, Toshiaki Okuno, Yasuyuki Ohkawa, Takehiko Yokomizo.
Investigation: Fumiyuki Sasaki, Takehiko Yokomizo.

Methodology: Fumiyuki Sasaki, Tsutomu Fujimura, Yasuyuki Ohkawa, Takehiko Yokomizo.

Project administration: Fumiyuki Sasaki, Takehiko Yokomizo.

Resources: Fumiyuki Sasaki, Tomoaki Koga, Kazuko Saeki, Toshiaki Okuno, Saiko Kazuno, Tsutomu Fujimura, Yasuyuki Ohkawa, Takehiko Yokomizo.

Supervision: Takehiko Yokomizo.

Validation: Fumiyuki Sasaki.

Visualization: Fumiyuki Sasaki.

Writing – original draft: Fumiyuki Sasaki, Takehiko Yokomizo.

Writing – review & editing: Fumiyuki Sasaki, Tomoaki Koga, Kazuko Saeki, Toshiaki Okuno, Saiko Kazuno, Tsutomu Fujimura, Yasuyuki Ohkawa, Takehiko Yokomizo.

References
1. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997; 387(6633):620–624. https://doi.org/10.1038/42506 PMID: 9177352.

2. Huang WW, Garcia-Zepeda EA, Sauty A, Oettgen HC, Rothenberg ME, Luster AD. Molecular and biological characterization of the murine leukotriene B4 receptor expressed on eosinophils. J Exp Med. 1998; 188(6):1063–1074. PMID: 9743525.

3. Yokomizo T. Two distinct leukotriene B4 receptors, BLT1 and BLT2. J Biochem. 2015; 157(2):65–71. https://doi.org/10.1093/jb/mvu078 PMID: 25480980.

4. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol. 2009; 49:123–150. https://doi.org/10.1146/annurev.pharmtox.011008.145616 PMID: 18834304.

5. Nakamura M, Shimizu T. Leukotriene receptors. Chem Rev. 2011; 111(10):6231–6298. https://doi.org/10.1021/cr100392s PMID: 21526749.

6. Hanibabu B, Verghese MW, Steeber DA, Sellars DD, Bock CB, Snyderman R. Targeted disruption of the leukotriene B(4) receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J Exp Med. 2000; 192(3):433–438. PMID: 10934231.

7. Tager AM, Dufour JH, Goodarzi K, Bercury SD, von Andrian UH, Luster AD. BLTR mediates leukotriene B(4)-induced chemotaxis and adhesion and plays a dominant role in eosinophil accumulation in a murine model of peritonitis. J Exp Med. 2000; 192(3):439–446. PMID: 10934232.

8. Miyahara N, Ohnishi H, Matsuda H, Miyahara S, Takeda K, Koya T, et al. Leukotriene B4 receptor 1 expression on dendritic cells is required for the development of Th2 responses and allergen-induced airway hypersensitivity. J Immunol. 2008; 181(2):1170–1178. PMID: 18606670.

9. Toda A, Terawaki K, Yarnazaki S, Saeki K, Shimizu T, Yokomizo T. Attenuated Th1 induction by dendritic cells from mice deficient in the leukotriene B4 receptor 1. Biochimie. 2010; 92(6):682–691. https://doi.org/10.1016/j.bioch.2009.12.002 PMID: 20004699.

10. Friedrich EB, Tager AM, Liu E, Pettersson A, Owman C, Munn L, et al. Mechanisms of leukotriene B4—triggered monocyte adhesion. Arterioscler Thromb Vasc Biol. 2003; 23(10):1761–1767. https://doi.org/10.1161/01.ATV.0000105033.16635.15 PMID: 14656734.

11. Subbarao K, Jala VR, Mathis S, Suttles J, Zacharias W, Ahamed J, et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol. 2004; 24(2):369–375. https://doi.org/10.1161/01.ATV.0000105033.16635.15 PMID: 14656734.

12. Lundeen KA, Sun B, Karlsson L, Fourie AM. Leukotriene B4 receptors BLT1 and BLT2: expression and function in human and murine mast cells. J Immunol. 2006; 177(5):3439–3447. PMID: 16920986.

13. Hikiji H, Ishii S, Yokomizo T, Takato T, Shimizu T. A distinctive role of the leukotriene B4 receptor BLT1 in osteoclastic activity during bone loss. Proc Natl Acad Sci U S A. 2009; 106(50):21294–21299. https://doi.org/10.1073/pnas.0905209106 PMID: 19965376.
14. Goodarzi K, Goodarzi M, Tager AM, Luster AD, von Andrian UH. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol. 2003; 4(10):965–973. https://doi.org/10.1038/ni972 PMID: 12949533.

15. Ott VL, Cambier JC, Kappler J, Marrack P, Swanson BJ. Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol. 2003; 4(10):974–981. https://doi.org/10.1038/ni971 PMID: 12949532.

16. Tager AM, Bromley SK, Medoff BD, Islam SA, Bercury SD, Friedrich EB, et al. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol. 2003; 4(10):982–990. https://doi.org/10.1038/ni970 PMID: 12949531.

17. Scott MJ, Cheadle WG, Hoth JJ, Peyton JC, Subbarao K, Shao WH, et al. Leukotriene B4 receptor (BLT-1) modulates neutrophil influx into the peritoneum but not the lung and liver during surgically induced bacterial peritonitis in mice. Clin Diagn Lab Immunol. 2004; 11(5):936–941. https://doi.org/10.1128/CDLI.11.5.936-941.2004 PMID: 15358656.

18. Kim ND, Chou RC, Seung E, Tager AM, Luster AD. A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J Exp Med. 2006; 203(4):829–835. https://doi.org/10.1084/jem.20052349 PMID: 16567386.

19. Afonso PV, Janka-Junttila M, Lee YJ, McCann CP, Oliver CM, Aamer KA, et al. Leukotriene B4 type-1 receptor signaling promotes liver repair after hepatic ischemia/reperfusion injury through the enhancement of macrophage recruitment. FASEB J. 2013; 27(8):3132–3143. https://doi.org/10.1096/fj.13-227421 PMID: 23629862.

20. Ohkubo H, Ito Y, Minamino T, Mishima T, Hirata M, Hosono K, et al. Leukotriene B4 type-1 receptor signaling augments and restores Fc gammaRs-dependent phagocytosis in macrophages. J Biol Chem. 2010; 285(52):41113–41121. https://doi.org/10.1074/jbc.M110.175497 PMID: 20994940.

21. Lammermann T, Afonso PV, Angermann BR, Wang JM, Kastenmüller W, Parent CA, et al. Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo. Nature. 2013; 498(7454):371–375. https://doi.org/10.1038/nature12175 PMID: 23708969.

22. Serezani CH, Aronoff DM, Sitrin RG, Peters-Golden M. Fc gammaRI ligation leads to a complex with BLT1 in lipid rafts that enhances rat lung macrophage antimicrobial functions. Blood. 2009; 114(15):3316–3324. https://doi.org/10.1182/blood-2009-01-199915 PMID: 19657115.

23. Okamoto F, Saeki K, Sumimoto H, Yamasaki S, Yokomizo T. Leukotriene B4 augments and restores BLT2 receptor s in atherosclerosis. Cardiovasc Res. 2009; 81(1):216–225. https://doi.org/10.1093/cvr/cvn277 PMID: 18852255.

24. Soares EM, Mason KL, Rogers LM, Serezani CH, Faccioli LH, Aronoff DM. Leukotriene B4 enhances innate immune defense against the puerperal sepsis agent Streptococcus pyogenes. J Immunol. 2013; 190(4):1614–1622. https://doi.org/10.4049/jimmunol.1200257 PMID: 23325886.

25. Sanchez-Galan E, Gomez-Hernandez A, Vidal C, Martin-Ventura JL, Blanco-Colio LM, Munoz-Garcia B, et al. Leukotriene B4 augments the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovasc Res. 2009; 81(1):216–225. https://doi.org/10.1093/cvr/cvn277 PMID: 18852255.

26. Serezani CH, Kané S, Collins L, Morato-Marques M, Osterhozer JJ, Peters-Golden M. Macrophage dectin-1 expression is controlled by leukotriene B4 via a GM-CSF/PU.1 axis. J Immunol. 2012; 189(2):906–915. https://doi.org/10.4049/jimmunol.1200257 PMID: 22696442.

27. Li P, Oh DY, Bandypadhyay G, Lagakos WS, Talukdar S, Osborn O, et al. LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat Med. 2015; 21(3):239–247. https://doi.org/10.1038/nm.3800 PMID: 25706874.

28. Ichiki T, Koga T, Okuno T, Saeki K, Yamamoto Y, Yamamoto H, et al. Modulation of leukotriene B4 receptor 1 signaling by receptor for advanced glycation end products (RAGE). FASEB J. 2016; 30(5):1811–1822. https://doi.org/10.1096/fj.201500117 PMID: 26815973.

29. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000; 343(22):1594–1602. https://doi.org/10.1056/NEJM200011303432202 PMID: 11096166.

30. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004; 350(25):2572–2581. https://doi.org/10.1056/NEJMoa032534 PMID: 15201414.

31. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006; 54(9):2817–2829. https://doi.org/10.1002/art.22033 PMID: 16947782.
32. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. Crohn’s Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. N Engl J Med. 1997; 337(15):1029–1035. https://doi.org/10.1056/NEJM19971009371502 PMID: 9321530.

33. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanss J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012; 367(16):1519–1528. https://doi.org/10.1056/NEJMoa1203572 PMID: 23075178.

34. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013; 369(8):711–721. https://doi.org/10.1056/NEJMoa1215739 PMID: 23964933.

35. Nagata K, Hirai H, Tanaka K, Ogawa K, Aso T, Sugamura K, et al. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett. 1999; 459(2):195–199. PMID: 10518017.

36. Pettersson A, Boketoft A, Sabirsh A, Nilsson NE, Kotarsky K, Olde B, et al. First-generation monoclonal antibodies identifying the human leukotriene B(4) receptor-1. Biochem Biophys Res Commun. 2000; 279(2):520–525. https://doi.org/10.1006/bbrc.2000.3989 PMID: 11118319.

37. Rieselsman M, Miettinen HM, Grippentrog JM, Lord CI, Mumey B, Dratz EA, et al. C-terminal tail phosphorylation of N-formyl peptide receptor: differential recognition of two neutrophil chemoattractant receptors by monoclonal antibodies NFPR1 and NFPR2. J Immunol. 2007; 179(4):2520–2531. PMID: 17675514.

38. Harris GL, Creason MB, Brulte GB, Herr DR. In vitro and in vivo antagonism of a G protein-coupled receptor (S1P3) with a novel blocking monoclonal antibody. PLoS One. 2012; 7(4):e35129. https://doi.org/10.1371/journal.pone.0035129 PMID: 22496900.

39. Nagata N, Iwari H, Kumagai H, Kusano-Arai O, Ikeda Y, Aritake K, et al. Generation and characterization of an agonistic monoclonal antibody against an extracellular domain of mouse DP2 (CRTH2/GPR44) receptors for prostaglandin D2. PLoS One. 2017; 12(4):e0175452. https://doi.org/10.1371/journal.pone.0175452 PMID: 28394950.

40. Fraser CM, Venter JC. Monoclonal antibodies to beta-adrenergic receptors: use in purification and molecular characterization of beta receptors. Proc Natl Acad Sci U S A. 1980; 77(12):7034–7038. PMID: 6261236.

41. Shimada M, Chen X, Cvrrk T, Hilfiker H, Parfenova M, Segre GV. Puriﬁcation and characterization of a receptor for human parathyroid hormone and parathyroid hormone-related peptide. J Biol Chem. 2002; 277(35):31774–31780. https://doi.org/10.1074/jbc.M204166200 PMID: 12080067.

42. AbdAlla S, Lother H, Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and beta-arrestin-mediated internalization of CCR5 homo- and hetero-oligomers. J Biol Chem. 2005; 280(45):37503–37515. https://doi.org/10.1074/jbc.M500535200 PMID: 16144840.

43. Hernanz-Falcon P, Rodriguez-Frade JM, Serrano A, Juan D, del Sol A, Soriano SF, et al. Identification of amino acid residues crucial for chemokine receptor dimerization. Nat Immunol. 2004; 5(2):216–223. https://doi.org/10.1038/n10127 PMID: 14716303.

44. Hutterer E, P-lott-Kopp B, Oppermann M. G protein-coupled receptor kinases promote phosphorylation and beta-arrestin-mediated internalization of COR5 homo- and hetero-oligomers. J Biol Chem. 2005; 280(45):37503–37515. https://doi.org/10.1074/jbc.M500535200 PMID: 16144840.

45. Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR, et al. Immunosuppressive and antiangiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitylation and proteasomal degradation of the receptor. J Biol Chem. 2007; 282(12):9082–9089. https://doi.org/10.1074/jbc.M610318200 PMID: 17237497.

46. Galvani S, Sanson M, Blaho VA, Swendeman SL, Obinata H, Conger H, et al. HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation. Sci Signal. 2015; 8(389):ra79. https://doi.org/10.1126/scisignal.aaa2581 PMID: 26268607.

47. Day PW, Rasmussen SG, Parnot C, Fung JJ, Masood A, Kobilka TS, et al. Monoclonal antibodies identifying the human leukotriene B(4) receptor-1. Biochem Biophys Res Commun. 2000; 279(2):520–525. https://doi.org/10.1006/bbrc.2000.3989 PMID: 11118319.

48. Majumdar R, Railkar R, Dighe RR. Insights into differential modulation of receptor function by hinge region using novel agonistic lutropin receptor and inverse agonistic thyrotropin receptor antibodies. FEBS Lett. 2012; 586(6):810–817. https://doi.org/10.1016/j.febslet.2012.01.052 PMID: 22309849.
51. Hagemann UB, Gunnarsson L, Geraudie S, Scheffler U, Griep RA, Reiersen H, et al. Fully human antagonistic antibodies against CCR4 potently inhibit cell signaling and chemotaxis. PLoS One. 2014; 9(7):e103776. https://doi.org/10.1371/journal.pone.0103776 PMID: 25080123.

52. Peyrassol X, Laeremans T, Gouwy M, Lahura V, Debulpaep M, Van Damme J, et al. Development by Genetic Immunization of Monovalent Antibodies (Nanobodies) Behaving as Antagonists of the Human ChemR23 Receptor. J Immunol. 2016; 196(6):2893–2901. https://doi.org/10.4049/jimmunol.1500888 PMID: 26864035.

53. Terawaki K, Yokomizo T, Nagase T, Toda A, Taniguchi M, Hashizume K, et al. Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses. J Immunol. 2005; 175(7):4217–4225. PMID: 16177061.

54. Iizuka Y, Okuno T, Saeki K, Uozaki H, Okada S, Misaka T, et al. Protective role of the leukotriene B4 receptor BLT2 in murine inflammatory colitis. FASEB J. 2010; 24(12):4678–4690. https://doi.org/10.1096/fj.10-165050 PMID: 20667973.

55. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991; 108(2):193–199. PMID: 1660837.

56. Sasaki F, Okuno T, Saeki K, Min L, Onohara N, Kato H, et al. A high-affinity monoclonal antibody against the FLAG tag useful for G-protein-coupled receptor study. Anal Biochem. 2012; 425(2):157–165. https://doi.org/10.1016/j.ab.2012.03.014 PMID: 22465329.

57. Kuniyeda K, Okuno T, Terawaki K, Miyano M, Yokomizo T, Shimizu T. Identification of the intracellular region of the leukotriene B4 receptor type 1 that is specifically involved in Gi activation. J Biol Chem. 2007; 282(6):3998–4006. https://doi.org/10.1074/jbc.M610542020 PMID: 17158791.

58. Castrop J, Verbeek S, Hofhuis F, Clevers H. Circumvention of tolerance for the nuclear T cell protein TCF-1 by immunization of TCF-1 knock-out mice. Immunobiology. 1995; 193(2–4):281–287. https://doi.org/10.1016/S0171-2985(11)80556-5 PMID: 8530156.

59. Pass J, Gardsvoll H, Lund LR, Dano K, Hoyer-Hansen G. Generation of antibodies to the urokinase receptor (uPAR) by DNA immunization of uPAR knockout mice: membrane-bound uPAR is not required for an antibody response. Scand J Immunol. 2003; 58(3):298–305. PMID: 12950675.

60. Matsumoto Y, Takizawa H, Gong X, Le S, Lockyer S, Okuyama K, et al. Highly potent anti-human GPVI monoclonal antibodies derived from GPVI knockout mouse immunization. Thromb Res. 2007; 119(3):319–329. https://doi.org/10.1016/j.thromres.2006.01.023 PMID: 16566959.

61. Pass J, Jogi A, Lund IK, Rono B, Rasch MG, Gardsvoll H, et al. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo. Thromb Haemost. 2007; 97(6):1013–1022. PMID: 17549305.

62. Hrabovská A, Bernard V, Krečí E. A novel system for the efficient generation of antibodies following immunization of unique knockout mouse strains. PLoS One. 2010; 5(9):e12892. https://doi.org/10.1371/journal.pone.0012892 PMID: 20886120.

63. Cheong C, Matos I, Choi JH, Schauer JD, Dandamudi DB, Shrestha E, et al. New monoclonal anti-mouse DC-SIGN antibodies reactive with acetone-fixed cells. J Immunol Methods. 2010; 360(1–2):66–75. https://doi.org/10.1016/j.jim.2010.06.006 PMID: 20558171.

64. Sabirsh A, Bywater RP, Bristulf J, Owman C, Haeggstrom JZ. Residues from transmembrane helices 3 and 5 participate in leukotriene B4 binding to BLT1. Biochemistry. 2006; 45(18):5733–5744. https://doi.org/10.1021/bi060076s PMID: 16696167.

65. Basu S, Jala VR, Mathis S, Rajagopal ST, Del Prete A, Maturu P, et al. Critical role for polar residues in coupling leukotriene B4 binding to signal transduction in BLT1. J Biol Chem. 2007; 282(13):10005–10017. https://doi.org/10.1074/jbc.M609552200 PMID: 17237498.

66. Martin A, Damian M, Laguerre M, Parello J, Pucci B, Serre L, et al. Engineering a G protein-coupled receptor for structural studies: stabilization of the BLT1 receptor ground state. Protein Sci. 2009; 18(4):727–734. https://doi.org/10.1002/pro.55 PMID: 19309698.

67. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005; 5(12):953–964. https://doi.org/10.1038/nri1733 PMID: 16322748.

68. Varol C, Mildner A, Jung S. Macrophages: development and tissue specialization. Annu Rev Immunol. 2015; 33:643–675. https://doi.org/10.1146/annurev-immunol-032414-112220 PMID: 25861979.

69. Tussiwand R, Gautier EL. Transcriptional Regulation of Mononuclear Phagocyte Development. Front Immunol. 2015; 6:533. https://doi.org/10.3389/fimmu.2015.00533 PMID: 26539196.

70. Auffray C, Fogg D, Garfa M, Elain G, Join-Lambert O, Kayal S, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007; 317(5838):666–670. https://doi.org/10.1126/science.1142883 PMID: 17673663.
71. Arnold L, Henry A, Poron F, Baba-Amer Y, van Rooijen N, Plonquet A, et al. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J Exp Med. 2007; 204(5):1057–1069. https://doi.org/10.1084/jem.20070075 PMID: 17485518.

72. Egawa M, Mukai K, Yoshikawa S, Iki M, Mukaida N, Kawano Y, et al. Inflammatory monocytes recruited to allergic skin acquire an anti-inflammatory M2 phenotype via basophil-derived interleukin-4. Immunity. 2013; 38(3):570–580. https://doi.org/10.1016/j.immuni.2012.11.014 PMID: 23434060.